北米の動物用調剤薬局市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品別、動物タイプ別、エンドユーザー別、国別

北米の動物用調剤薬局の市場規模は近年、堅調な成長を遂げています。この拡大は、ペットの飼い主の間で動物の健康に関する意識が高まり、動物のさまざまな症状の治療に調剤薬が果たす重要な役割が認識されたことが主な要因です。市場は今後も上昇傾向が続くと予想されており、2024年には14億8,000万米ドル、2031年には27億米ドルに達すると予測されています。

市場の成長を牽引する主な要因は、飼い主の間でペットの健康に対する意識が高まっていることです。米国ペット製品協会と米国獣医師会（AVMA）の報告によると、米国では約8,490万世帯がペットを飼っています。ペットの飼育数の増加により、獣医によるケアや特定のニーズに合わせた調合薬の需要が高まっています。

動物用ジェネリック薬の高価格と入手のしやすさも、市場拡大の要因となっています。認可された調剤薬局は、高価なブランド薬よりもこうした薬を好むペットの飼い主に、より手頃で入手しやすい選択肢を提供します。この傾向は、ペットのケア費用が法外な低所得世帯で特に顕著です。

当レポートでは、北米の動物用調剤薬局市場について調査し、市場の概要とともに、製品別、動物タイプ別、エンドユーザー別、国別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 市場の定義とセグメンテーション
• 市場力学
• 採用率/使用状況分析- 主要統計
• バリューチェーン分析
• 規制シナリオ
• 製品のUSP分析
• ポーターのファイブフォース分析
• COVID-19の影響分析
• 経済概要
• PESTLE分析

第3章 北米の動物用調剤薬局市場の見通し、2019年～2031年

• 北米の動物用調剤薬局市場の見通し、製品別、金額（10億米ドル）、2019年～2031年
• 北米の動物用調剤薬局市場の見通し、動物タイプ別、金額（10億米ドル）、2019年～2031年
• 北米の動物用調剤薬局市場の見通し、エンドユーザー別、金額（10億米ドル）、2019年～2031年
• 北米の動物用調剤薬局市場の見通し、国別、金額（10億米ドル）、2019年～2031年

第4章 米国の動物用調剤薬局市場の見通し、2019年～2031年

第5章 カナダの動物用調剤薬局市場の見通し、2019年～2031年

第6章 競合情勢

• 企業市場シェア分析、2023年
• 競合ダッシュボード
• 企業プロファイル
  • Hoye's Pharmacy
  • Vertisis Custom Pharmacy
  • Smith Caldwell Drug Store
  • Sixth Avenue Medical Pharmacy
  • Dougherty Pharmacy
  • Triangle Compounding Pharmacy Inc.,
  • Wedgewood Pharmacy
  • Millers Pharmacy
  • Chiron Compounding Pharmacy
  • MEDS Canadian Compounding Pharmacy
  • Aurora Compounding
  • Pace Pharmacy

第7章 付録

The North American veterinary compounding pharmacies market has experienced robust growth in recent years. This expansion is largely driven by the increasing awareness among pet owners about animal health and the critical role of compounded medications in treating various conditions in animals. The market is expected to continue its upward trajectory, with a projected size of US$ 1.48 billion in 2024 and US$ 2.7 billion by 2031.

Key Drivers of Market Growth

Increasing Awareness and Pet Ownership

A primary factor propelling market growth is the heightened awareness of pet health among owners. Reports from the American Pet Product Association and the American Veterinary Medical Association (AVMA) indicate that nearly 84.9 million households in the U.S. own pets. This rise in pet ownership has led to a greater demand for veterinary care and compounded medications tailored to specific needs.

Cost and Availability of Generic Veterinary Drugs

The high cost and limited availability of generic veterinary drugs have also contributed to market expansion. Authorized compounding pharmacies provide more affordable and accessible options for pet owners, who often find these medications preferable to expensive branded drugs. This trend is especially notable in low-income households where the cost of animal care can be prohibitive.

Market Segmentation

CNS Agents Leading the Market

The CNS agents segment is anticipated to hold the largest market value, reaching approximately US$ 517.6 million in 2023. CNS medications are crucial for treating conditions such as attention deficit hyperactivity disorder (ADHD) in companion animals, particularly dogs, significantly contributing to market growth.

Companion Animals Dominate the Market

The companion animal segment, driven by the growing humanization of pets and increasing adoption rates, is expected to dominate the market. This segment is projected to hold around 58.7% of the market share.

Oral Formulations Preferred

Oral formulations are the most preferred method of drug administration in the veterinary sector due to their non-invasive nature, ease of administration, and patient compliance. This segment is expected to capture approximately 75.3% of the market share.

Regional Insights

U.S. Market Holds Significant Share

The U.S. is projected to maintain its dominance in the North American vet compounding pharmacies market, holding around 87.9% of the regional market share. The country's robust regulatory environment, expanding pharmaceutical sector, and increasing demand for diverse animal medications are key factors contributing to its leading position.

Canada's Growing Market Share

Canada is expected to hold a market share of around 12.1%. The increasing popularity of pet ownership and heightened awareness of animal healthcare are driving market growth in the country. Additionally, the introduction of new products by major players is bolstering the market.

Competitive Analysis

Leading companies in the North American vet compounding pharmacies market are focusing on expanding their customer base and enhancing their market presence through the development and launch of new and improved medications. The top four companies account for approximately 35.8% of the market share.

Key Developments

In January 2021, the FDA issued a recommendation titled GFI #256, outlining the conditions under which it would not enforce laws against the bulk manufacturing of medications. This recommendation supports the development of necessary antidotes for poisons found in animal food and significant differences between compounded medications and FDA-approved drugs with the same active ingredients.

In October 2020, Virbac introduced STELFONTA, a novel injectable treatment for canine mast cell tumors, the most common form of skin cancer in dogs. This treatment demonstrated a high rate of tumor eradication and marked a significant advancement in veterinary oncology.

Key Market Players Include:

Hoye's Pharmacy

Vertisis Custom Pharmacy

Smith Caldwell Drug Store

Sixth Avenue Medical Pharmacy

Dougherty Pharmacy

Triangle Compounding Pharmacy Inc.

Wedgewood Pharmacy

Millers Pharmacy

Chiron Compounding Pharmacy

MEDS Canadian Compounding Pharmacy

Aurora Compounding

Pace Pharmacy

Victoria Compounding Pharmacy

Pratt's Compounding Pharmacy

People's Choice Pharmacy

Global North America Vet Compounding Pharmacies Market Segmentation:

By Product:

CNS Agents

Anti-Infective Agents

Hormones and Substitutes

Anti-inflammatory Agents

Others

By Animal Type:

Companion Animals

Dogs

Cats

Equine

Others

Livestock Animals

By End User:

Oral

Injectable

Others

By Country:

U.S.

Canada

Table of Contents

1. Executive Summary

• 1.1. North America Vet Compounding Pharmacies Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Adoption Rate/Usage Analysis - Key Statistics
• 2.4. Value Chain Analysis
• 2.5. Regulatory Scenario
• 2.6. Product USP Analysis
• 2.7. Porter's Five Forces Analysis
• 2.8. COVID-19 Impact Analysis
  • 2.8.1. Supply
  • 2.8.2. Demand
• 2.9. Economic Overview
  • 2.9.1. World Economic Projections
• 2.10. PESTLE Analysis

3. North America Vet Compounding Pharmacies Market Outlook, 2019 - 2031

• 3.1. North America Vet Compounding Pharmacies Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. CNS Agents
    • 3.1.1.2. Anti-Infective Agents
    • 3.1.1.3. Hormones and Substitutes
    • 3.1.1.4. Anti-inflammatory Agents
    • 3.1.1.5. Others
• 3.2. North America Vet Compounding Pharmacies Market Outlook, by Animal Type, Value (US$ Bn), 2019 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Companion Animals
      • 3.2.1.1.1. Dogs
      • 3.2.1.1.2. Cats
      • 3.2.1.1.3. Equine
      • 3.2.1.1.4. Others
    • 3.2.1.2. Livestock Animals
• 3.3. North America Vet Compounding Pharmacies Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Oral
    • 3.3.1.2. Injectable
    • 3.3.1.3. Others
• 3.4. North America Vet Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. U.S.
    • 3.4.1.2. Canada

4. U.S. Vet Compounding Pharmacies Market Outlook, 2019 - 2031

• 4.1. U.S. Vet Compounding Pharmacies Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. CNS Agents
    • 4.1.1.2. Anti-Infective Agents
    • 4.1.1.3. Hormones and Substitutes
    • 4.1.1.4. Anti-inflammatory Agents
    • 4.1.1.5. Others
• 4.2. U.S. Vet Compounding Pharmacies Market Outlook, by Animal Type, Value (US$ Bn), 2019 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Companion Animals
      • 4.2.1.1.1. Dogs
      • 4.2.1.1.2. Cats
      • 4.2.1.1.3. Equine
      • 4.2.1.1.4. Others
    • 4.2.1.2. Livestock Animals
• 4.3. U.S. Vet Compounding Pharmacies Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Oral
    • 4.3.1.2. Injectable
    • 4.3.1.3. Others
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Canada Vet Compounding Pharmacies Market Outlook, 2019 - 2031

• 5.1. Canada Vet Compounding Pharmacies Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. CNS Agents
    • 5.1.1.2. Anti-Infective Agents
    • 5.1.1.3. Hormones and Substitutes
    • 5.1.1.4. Anti-inflammatory Agents
    • 5.1.1.5. Others
• 5.2. Canada Vet Compounding Pharmacies Market Outlook, by Animal Type, Value (US$ Bn), 2019 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Companion Animals
      • 5.2.1.1.1. Dogs
      • 5.2.1.1.2. Cats
      • 5.2.1.1.3. Equine
      • 5.2.1.1.4. Others
    • 5.2.1.2. Livestock Animals
• 5.3. Canada Vet Compounding Pharmacies Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Oral
    • 5.3.1.2. Injectable
    • 5.3.1.3. Others
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Competitive Landscape

• 6.1. Company Market Share Analysis, 2023
• 6.2. Competitive Dashboard
• 6.3. Company Profiles
  • 6.3.1. Hoye's Pharmacy
    • 6.3.1.1. Company Overview
    • 6.3.1.2. Product Portfolio
    • 6.3.1.3. Financial Overview
    • 6.3.1.4. Business Strategies and Development
  • 6.3.2. Vertisis Custom Pharmacy
    • 6.3.2.1. Company Overview
    • 6.3.2.2. Product Portfolio
    • 6.3.2.3. Financial Overview
    • 6.3.2.4. Business Strategies and Development
  • 6.3.3. Smith Caldwell Drug Store
    • 6.3.3.1. Company Overview
    • 6.3.3.2. Product Portfolio
    • 6.3.3.3. Financial Overview
    • 6.3.3.4. Business Strategies and Development
  • 6.3.4. Sixth Avenue Medical Pharmacy
    • 6.3.4.1. Company Overview
    • 6.3.4.2. Product Portfolio
    • 6.3.4.3. Financial Overview
    • 6.3.4.4. Business Strategies and Development
  • 6.3.5. Dougherty Pharmacy
    • 6.3.5.1. Company Overview
    • 6.3.5.2. Product Portfolio
    • 6.3.5.3. Financial Overview
    • 6.3.5.4. Business Strategies and Development
  • 6.3.6. Triangle Compounding Pharmacy Inc.,
    • 6.3.6.1. Company Overview
    • 6.3.6.2. Product Portfolio
    • 6.3.6.3. Financial Overview
    • 6.3.6.4. Business Strategies and Development
  • 6.3.7. Wedgewood Pharmacy
    • 6.3.7.1. Company Overview
    • 6.3.7.2. Product Portfolio
    • 6.3.7.3. Financial Overview
    • 6.3.7.4. Business Strategies and Development
  • 6.3.8. Millers Pharmacy
    • 6.3.8.1. Company Overview
    • 6.3.8.2. Product Portfolio
    • 6.3.8.3. Financial Overview
    • 6.3.8.4. Business Strategies and Development
  • 6.3.9. Chiron Compounding Pharmacy
    • 6.3.9.1. Company Overview
    • 6.3.9.2. Product Portfolio
    • 6.3.9.3. Financial Overview
    • 6.3.9.4. Business Strategies and Development
  • 6.3.10. MEDS Canadian Compounding Pharmacy
    • 6.3.10.1. Company Overview
    • 6.3.10.2. Product Portfolio
    • 6.3.10.3. Financial Overview
    • 6.3.10.4. Business Strategies and Development
  • 6.3.11. Aurora Compounding
    • 6.3.11.1. Company Overview
    • 6.3.11.2. Product Portfolio
    • 6.3.11.3. Financial Overview
    • 6.3.11.4. Business Strategies and Development
  • 6.3.12. Pace Pharmacy
    • 6.3.12.1. Company Overview
    • 6.3.12.2. Product Portfolio
    • 6.3.12.3. Financial Overview
    • 6.3.12.4. Business Strategies and Development

7. Appendix

• 7.1. Research Methodology
• 7.2. Report Assumptions
• 7.3. Acronyms and Abbreviations

List of Region/Countries

• North America
  • U.S.
  • Canada